Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. - Wikidata - wikimedia - TriplyDB

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

http://www.wikidata.org/entity/Q35657628

about

Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses Synthetic self-adjuvanting glycopeptide cancer vaccines Challenges in Antibody Development against Tn and Sialyl-Tn Antigens Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification Glycotherapy: new advances inspire a reemergence of glycans in medicine Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Total synthesis of glycosylated proteins Molecular mimics of the tumour antigen MUC1 Sialyl-tn in cancer: (how) did we miss the target?Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers MUC1: a multifaceted oncoprotein with a key role in cancer progression.Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Altered Mucins (MUC) trafficking in benign and malignant conditions.Liposomes as vaccine delivery systems: a review of the recent advances.Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.Genetically engineered mice as experimental tools to dissect the critical events in breast cancer Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche Immunotherapeutic approaches to ovarian cancer treatment.Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen.A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.Tecemotide: an antigen-specific cancer immunotherapy.Tumor-Associated Glycans and Immune Surveillance MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.Genetically engineered mucin mouse models for inflammation and cancer.Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice Two opposing roles of O-glycans in tumor metastasis.Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.Molecular basis of antibody binding to mucin glycopeptides in lung cancer Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.

P2860

Q26740513-5EC49CD1-4E5E-45D4-B50E-2B5AD6B9E5AB Q26746887-F9C4009F-6F49-4EA4-89F1-A2494CEB361E Q26777837-5FBC19B4-7B5B-41E8-BAEC-BE3A9114FF34 Q26798183-CECAFDAB-E3B7-407D-9BA6-8CA5D68B9282 Q27001592-B52328CB-17E2-4E25-AD3C-B88ABD56CE0F Q27027997-BEFB4D70-A884-418B-9761-9BF7DD89F354 Q28071998-53E21838-4037-4F42-8AED-5836E38E458B Q28083496-A6EA5F9F-0EBF-45BD-B160-2879F5EADD0A Q28485169-05519CA6-DE07-4C52-B830-60A45D5AC404 Q33649572-49D2888E-672D-4464-88FD-0300F08660C2 Q33819711-32A20556-7A7D-4182-8199-8672C77DEB84 Q33880143-A86237C6-3977-4D3F-84FF-0CBA1DA439AD Q33961477-C36E6395-9C1C-4FAC-B0C8-E58837943224 Q34365646-99343DF5-1D74-4D36-8C3B-F20C786A7BCB Q34418761-7332C423-19B9-4E4F-A8F0-BA8CE4802420 Q34478719-E464B3D7-EDBF-4F40-94E8-85CE3DC59A46 Q34489424-9292B404-A69B-4B61-A526-AECA81FABFC2 Q34494018-727445C6-F224-494F-8DEA-072D23C99BF3 Q34901076-C33A0D29-E6CD-4EAE-B50C-27ABBEF25E8E Q34988382-4408515F-F334-498C-80E2-E16E6B1D7453 Q35030845-565B4042-80C2-4419-BDA1-3D7EABD208A8 Q35146602-C082B8E0-BA04-4B24-AF94-C8BEF64459BD Q35201294-BB2E7A83-811C-4CAC-84A9-5031AD182281 Q35213535-A0E7DF1D-B5D9-4082-AF17-C5FF039391B6 Q35216220-BBBAF0B5-7C76-4095-8853-F6A30BB89C55 Q35684190-599B3F3F-34DB-45C2-AC45-7D762D321B41 Q35742481-2A3F0D8F-13F3-4D6B-8A67-8EAC8CF3EC3C Q35800918-61FB3B53-19CA-43F0-B396-C970DBAD9B7F Q35843039-66FCA9B3-0B8D-4847-86BD-AE1DCDFF4950 Q35886761-4F937B0D-BF13-4300-8AF2-798931651D89 Q35890610-0B9D1CE9-E373-4F0A-AE69-EC7D585DBBCB Q35898801-B96DB9E8-6200-499E-AB3D-9D27D16A1CD2 Q35904634-810F2FBF-95F5-4F6F-B180-CC5FB93B6187 Q35953085-73FD53C5-199C-45DC-B7CD-883D1E34FCB8 Q35972468-37F90EA8-8AAC-461F-A16F-B988C4717DF1 Q36221411-3754869D-82DF-4320-B197-4F3291A6056A Q36498123-95C776D1-21BA-42AF-B2E2-50E544975900 Q36544143-23427490-A1FA-4962-A9CB-46482B1191F2 Q36604334-120994D4-6FEA-43B4-8A1E-19BFDD53C96D Q36758192-98CBFFD0-E463-4810-A6E4-D0D1DB22FF54

P2860

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

http://www.wikidata.org/entity/Q35657628

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@ast

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@en

type

label

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@ast

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@en

prefLabel

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@ast

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@en

P1433

Q35657628-3428228D-011E-4881-9572-579B85BC76DC

P1476

Q35657628-E1C5DB08-F49C-4565-A9D1-25DB0A641EE8

P2093

Q35657628-5392E6C3-B017-4238-AD8B-F10B1278E691

Q35657628-5E5D0500-1CEF-40AD-AC3E-4774E06B1E1A

Q35657628-7023C95E-A24D-43B4-B9F1-82F0E9254A3D

Q35657628-960C878A-F8FC-4F88-B259-77D7934DD4BD

Q35657628-C085EC1E-D44B-499D-8D7E-4C64C65AC8B0

Q35657628-CBD7E133-7ACF-4E6F-8823-FA1FBC772122

Q35657628-F22FE09A-321C-487E-9E53-DE86EA16B8CA

P2860

Q35657628-06444472-7528-43A9-86BD-C9ECF16F748D

Q35657628-0D23C484-0A7A-4547-B24D-6B75A5C3FAE9

Q35657628-18C71548-3703-43C2-B3F2-F3ECB43D839F

Q35657628-1B3C303B-FE73-41A8-8502-8F8E1F790927

Q35657628-20B140B4-4B30-4CDE-A3F3-B0FA6353EDDC

Q35657628-219E45BE-1C93-4F37-959B-3339289827ED

Q35657628-313DD0DA-AF09-4040-ACC8-122BA1CC658C

Q35657628-39260B7E-7605-4DCF-AF36-6FEB9EFD019D

Q35657628-398B366F-7DB4-4862-B8E2-E7067843085C

Q35657628-3BD85634-030C-40F9-8F7E-6176BAC9DD09

P304

Q35657628-447F825E-AA0E-4170-996A-0D24D5FB8EF2

P31

Q35657628-3A52E9A6-1C3D-4FA8-BC68-A6C7DF6D03CF

P356

Q35657628-8DCCAECB-7F45-4E3C-BBEE-54055105FE20

P407

Q35657628-C58BB37E-DBE4-4031-8F8D-74E2CCD05619

P433

Q35657628-820841C8-91A4-4027-9901-BCD7EC063D73

P478

Q35657628-67857457-881C-4DC6-842C-89AC19C2EA6E

P50

Q35657628-369D3889-D6B9-488E-A451-3B737FD3CE7F

Q35657628-4589839B-0595-42A3-93BB-6439A8345E9A

Q35657628-A2F5E7A5-E43D-4A78-984C-7574233D29A8

P577

Q35657628-0B9EB475-A588-46C4-A4C1-B9CF61C93BF9

P5875

Q35657628-5EE24B45-85AC-4FF4-AD7D-87C50000EC1E

P698

Q35657628-C4946E21-9F45-4DA9-B107-EC3897F3E600

P921

Q35657628-E02B0F10-F9D0-4F49-8819-034FE4442B12

P932

Q35657628-820DD7E9-A97F-418A-9630-FD368F1A3D2B

P356

PNAS.1115166109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.

@en

P2093

Cathy S Madsen

http://www.w3.org/2001/XMLSchema#string

Judy M Bradley

http://www.w3.org/2001/XMLSchema#string

Latha B Pathangey

http://www.w3.org/2001/XMLSchema#string

Pamela Thompson

http://www.w3.org/2001/XMLSchema#string

Peter A Cohen

http://www.w3.org/2001/XMLSchema#string

Sandra J Gendler

http://www.w3.org/2001/XMLSchema#string

Therese Buskas

http://www.w3.org/2001/XMLSchema#string

P2860

A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase

Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains

Toll-like receptors: critical proteins linking innate and acquired immunity

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis

Robust immune responses elicited by a fully synthetic three-component vaccine.

MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues.

Differential induction of innate immune responses by synthetic lipid a derivatives

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

P304

261-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1115166109

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Geert-Jan Boons

Margreet A Wolfert

Vani Lakshminarayanan

P577

2011-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51881124

http://www.w3.org/2001/XMLSchema#string

P698

22171012

http://www.w3.org/2001/XMLSchema#string

P921

P932

3252914

http://www.w3.org/2001/XMLSchema#string